$26.47▴ 2.20%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 54% below our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Pacira BioSciences, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days1 article
0 bullish1 neutral0 bearish
Why Pacira BioSciences Skyrocketed Today
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight